| 8:00 am | Early-Bird Conference (Summary of ASN Highlights)
- Summarize a selection of studies presented at the 2023 ASN
- Analyze the clinical pertinence of each of these studies
- Apply appropriate learnings to clinical practice
|
| 9:00 am | Opening Remarks: Dr. Michel Vallée, JQH president
|
| 9:15 – 10:00 am | New Developments in Diabetes in the Dialysis Setting with a Focus on Obesity
Dr. Philippe Caron
- Compare and contrast basal insulins used to initiate insulin therapy in HD patients
- Evaluate the various tools available to monitor glycemic control in HD patients, including the limits of each
- Explain how to initiate treatment using a GLP-1 agonist
- Summarize future directions in obesity treatment in the HD setting
|
| 10:55 – 10:45 am | Anticoagulation and End-stage Renal Disease
Dr. Thomas Mavrakanas
- Evaluate the risk of thrombosis and hemorrhage in ESRD patients
- Interpret the pharmacokinetic data available on DOACs in ESRD patients
- Summarize the results of RCTs in patients with atrial fibrillation (AF) and ESRD
- Assess therapeutic strategies in ESRD patients with AF and thromboembolic disease
|
| 10:45 - 11:00 am | Health Break |
| 11:00 – noon | Pierre-Nantel Conference
Tackling the Staggering Environmental Impact of Hemodialysis: Practical suggestions to jumpstart the conversion to green nephrology
Dr. Didier Aguilera
- Analyze the environmental impact of hemodialysis
- Summarize the findings of the Néphrologie Verte de la Société francophone de néphrologie, dialyse et transplantation (SFNDT) and the recommendations of the Guide to Best Practices in Green Nephrology
- Implement measures to reduce the carbon footprint of your own HD centre
|
| noon - 1:00 pm | Lunch |
| 1:00 –1:45 pm | Hemodiafiltration and Its Alternatives to Improve Purification
Dr. Alexandre Granger
- Review the basic concepts of hemodiafiltration
- Analyse the benefits of convective therapies
- Summarize the major clinical studies on HDF
- Assess other techniques to improve purification
|
| 1:45 –2:30 pm | Onco-Nephrology in Hemodialysis
Dr. Chris Chan
- Examine the link between anticancer drug toxicity and the development of acute renal lesions leading to the need for dialysis
- Assess the consequences of cancer in CKF patients on hemodialysis
- Evaluate anticancer dose adjustment initiatives to improve outcomes in patients with chronic renal insufficiency
|
| 2:30 pm | Closing Remarks: Dr Michel Vallée
|